News | May 14, 2025
Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
Investment demonstrates confidence in America’s commitment to science and innovation
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
Sharma brings a wealth of expertise in optimizing manufacturing processes for fermentation-based APIs and sterile injectables
Strengthening capabilities in Peptide Therapeutics and CDMO services
Asahi Kasei Life Science covers a broad range of bioprocess products and services
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202
Subscribe To Our Newsletter & Stay Updated
